Company Profile
Updated: 17-SEP-09Elan Pharmaceuticals
Public Subsidiary, Headquarters Location
800 Gateway Blvd., South San Francisco, CA 94080-7021, United States
(650)877-0900, (650)877-7669 fax, http://www.elan.com
Primary SIC: Commercial Physical & Bio Research, Primary NAICS: Research and Development in the Physical Sciences and Engineering Sciences
Description: Services: Service; neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain More
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Merrion Pharmaceuticals Selected To Present At Prestigious Ubs Global Life Sciences Conference.(Conference news)
Cancer Weekly; 11/17/2009; 1571 words; ...economic advantages and pharmaceutical marketers with new ways...agreements with several pharmaceutical companies. On January...Wilmington, NC, USA, Merrion Pharmaceuticals (www.merrionpharma...publicly listed specialty pharmaceutical company engaged in the...technologies acquired from Elan ...
Merrion Pharmaceuticals Announces Interim Management Report Outlining Successful Business and Financial Overview From the Last Six Months.
Cancer Weekly; 11/17/2009; 1325 words; ...About Merrion Pharmaceuticals: Merrion Pharmaceuticals (www.merrionpharma...listed specialty pharmaceutical company engaged...technologies acquired from Elan Corporation, plc...partners with other pharmaceutical companies in developing...Osteoporosis, Pharmaceuticals, Prostate ...
Merrion Pharmaceuticals Opens New Custom-Built Facility for the Rapid and Effective Development of New Products.
Clinical Trials Week; 11/16/2009; 1184 words; ...of products (see also Pharmaceuticals). Merrion will be holding...house event. About Merrion Pharmaceuticals: Merrion Pharmaceuticals (www.merrionpharma...publicly listed specialty pharmaceutical company engaged in the...technologies acquired from Elan Corporation, plc. Merrion...
Neuropathic Pain Drug Market Will Increase From $6 Billion in 2008 to $9.7 Billion in 2018.
PR Newswire; 11/16/2009; 961 words; ...Johnson/Grunenthal, Durect/King Pharmaceuticals and UCB, According to a New Report...leading research and advisory firms for pharmaceutical and healthcare issues, finds that...UCB's Vimpat and Durect/King Pharmaceuticals' Eladur. "Although none of the...percent lidocaine patch (Endo/Elan's ...
Philippines : Filipina scientist wins P4.6-M prize for snail toxin work.
TendersInfo; 11/12/2009; 718 words; ...Philippines. One of these peptides was developed by U.S. biotechnology firm Cognetix Corp. (later bought by Elan Pharmaceuticals) to produce the non-addictive drug Prialt Ziconotodine (or primary alternative to morphine). "It's very...
Services: Service; neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain
Recent News Articles
- US healthcare major Johnson & Johnson and Irish neuroscience-based biotech firm Elan have signed an agreement whereby J&J will acquire all the assets and rights related to Elan's Alzheimer's disease immunotherapy programme through a new company, and will also invest $1bn in Elan in exchange for an 18.4% holding.(Pharma briefs)(Elan Pharmaceuticals Inc.)(Brief article)
Chemistry and Industry - July 27, 2009 - News and FDA Updates for Nanosphere (Nasdaq:NSPH), Elan (NYSE:ELN), EPIX Pharmaceuticals, Inc. (OTC:EPIX) and Merck & Co. (NYSE:MRK).
M2 Presswire - July 22, 2009 - Zacks Bull and Bear of the Day Highlights: Alvarion Ltd, MBIA, Johnson & Johnson, Elan and Wyeth Pharmaceuticals.
Business Wire - July 06, 2009 - Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium.
PR Newswire - March 06, 2009
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning